- Policy
- Hanmi’s Rosuzet with annual sales of ₩99.1 billion
- by Lee, Tak-Sun Apr 13, 2021 05:46am
- Rosuzet (Hanmi, Rosuvastatin-Ezetimibe), a blockbuster drug with annual prescriptions of &8361;99.1 billion, expects to add a new dose. Rosuzet is currently licensed for three doses, and the new dose is known to contain unlicensed doses in Korea. According to industry sources on the 12th, Hanmi recently applied for a new dose of Rosuzet
- Policy
- Sanofi withdraws 'EVE QUICK' from domestic market
- by Lee, Tak-Sun Apr 13, 2021 05:46am
- Imported pain relievers that entered the Korean market late are not faring well in Korea's market. This is because brand products like Tylenol, Geborin, and EZN have already settled in the market, and the fierce competition ongoing between multiple companies has left no room for late entrants. As a result, Sanofi has withdrawn its li
- Company
- Lilly spent ₩9.7 billion in severance pay last year
- by An, Kyung-Jin Apr 13, 2021 05:46am
- Lilly Korea spent nearly &8361;10 billion last year as employee severance pay. At the end of last year, the Hope Retirement Program (ERP) was launched for all employees of the sales department, and the amount of severance pay has jumped more than five times from the previous year. According to Lilly Korea's audit report submitted to the F
- Policy
- New drug Leclaza, only drug price negotiations remain
- by Lee, Hye-Kyung Apr 13, 2021 05:45am
- 'Leclaza (Lazertinib)', a non-small cell lung cancer treatment by Yuhan Corporation, the 31st new drug developed in Korea, has passed the first step of reimbursement. After receiving approval from the Ministry of Food and Drug Safety on January 18, the HIRA's Pharmaceutical Benefits Advisory Committee recognized the appropriateness of reimbur
- Company
- Yuhan distributed gold rings to all employees
- by Kim, Jin-Gu Apr 12, 2021 05:55am
- Yuhan recently handed out gold rings to former employees, showing Leclaza (Lazertinib)'s commitment to success. According to the industry on the 11th, Yuhan provided a gold ring with LECLAZA to all employees at the end of last February. It was only a month after receiving Conditional Marketing Authorization (CMA) as the 31st Korean drug on
- Policy
- 1st Gen. Economic Evaluation Expert Retires from Teaching
- by Lee, Hye-Kyung Apr 12, 2021 05:55am
- Chung-Ang University College of Pharmacy professor Dong-Churl Suh (65), an economics and policy expert in the domestic and foreign pharmaceutical industry, will be retiring in August this year. After graduating from Chung-Ang University College of Pharmacy in 1979, Suh went to the U.S. and obtained a Master of Business Administration fr
- Company
- Price hike of ‘Rotarix’ after ‘RotaTeq’ adds burden
- by Apr 12, 2021 05:54am
- The price of rotavirus vaccines for newborns is expected to increase altogether, with GSK also deciding to increase its supply price of ‘Rotarix’ after MSD’s price hike on ‘RotaTeq.’ Kwang Dong Pharmaceutical, the company in charge of the domestic supply of GSK’s Rotarix, recently sent a notice to clinics and hospitals on the de
- Company
- Local companies in panic over ‘Eliquis’ patent suit result
- by Kim, Jin-Gu Apr 9, 2021 05:56am
- The winner and loser of the long patent suit were reversed in the end. After losing the first and second trial, BMS finally got the upper hand in the fight with the generic manufacturers with a favorable ruling by the supreme court. On the other side, the generic companies are in hot water due to the unexpected result. In addition to im
- Policy
- Approval of Moderna's COVID-19 vaccine is imminent
- by Lee, Tak-Sun Apr 9, 2021 05:55am
- Moderna is applying for approval of COVID-19 vaccine from the MFDS sooner or later. It is reported that GC Pharma, in charge of the license and distribution of the vaccine, will have the necessary data for the license and will submit an application for approval next week as soon as possible. On the 8th, a government official said, "GC Phar
- Company
- Tagrisso’s 1st-line reimbursement rejected once again
- by Eo, Yun-Ho Apr 9, 2021 05:55am
- With ‘Tagrisso’ once again failing to expand its reimbursement, it seems that it may take a while for 3rd generation EGFR TKIs to be prescribed as 1st-line in Korea. According to industry sources, the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HIRA) decided it was inappropriate to expand the
